FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116724316> ?p ?o ?g. }

• W2116724316 endingPage "2198.e1" @default.
• W2116724316 startingPage "2188" @default.
• W2116724316 abstract "To evaluate the outcome of treatment with methotrexate for noninfectious ocular inflammation.Retrospective cohort study.Patients with noninfectious ocular inflammation managed at 4 tertiary ocular inflammation clinics in the United States observed to add methotrexate as a single, noncorticosteroid immunosuppressive agent to their treatment regimen, between 1979 and 2007, inclusive.Participants were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Demographic and clinical characteristics, including dosage, route of administration of methotrexate, and main outcome measures, were obtained for every eye of every patient at every visit via medical record review by trained expert reviewers.Control of inflammation, corticosteroid-sparing effects, and incidence of and reason for discontinuation of therapy.Among 384 patients (639 eyes) observed from the point of addition of methotrexate to an anti-inflammatory regimen, 32.8%, 9.9%, 21.4%, 14.6%, 15.1%, and 6.3%, respectively, had anterior uveitis, intermediate uveitis, posterior or panuveitis, scleritis, ocular mucous membrane pemphigoid, and other forms of ocular inflammation. In these groups, complete suppression of inflammation sustained for >or=28 days was achieved within 6 months in 55.6%, 47.4%, 38.6%, 56.4%, 39.5%, and 76.7%, respectively. Corticosteroid-sparing success (sustained suppression of inflammation with prednisone <or=10 mg/d) was achieved within 6 months among 46.1%, 41.3%, 20.7%, 37.3%, 36.5%, and 50.9%, respectively. Overall, success within 12 months was 66% and 58.4% for sustained control and corticosteroid sparing (<or=10 mg), respectively. Methotrexate was discontinued within 1 year by 42% of patients. It was discontinued owing to ineffectiveness in 50 patients (13%); 60 patients (16%) discontinued because of side effects, which typically were reversible with dose reduction or discontinuation. Remission was seen in 43 patients, with 7.7% remitting within 1 year of treatment.Our data suggest that adding methotrexate to an anti-inflammatory regimen not involving other noncorticosteroid immunosuppressive drugs is moderately effective for management of inflammatory activity and for achieving corticosteroid-sparing objectives, although many months may be required for therapeutic success. Methotrexate was well tolerated by most patients, and seems to convey little risk of serious side effects during treatment." @default.
• W2116724316 created "2016-06-24" @default.
• W2116724316 creator A5012888712 @default.
• W2116724316 creator A5016920591 @default.
• W2116724316 creator A5022396471 @default.
• W2116724316 creator A5031802215 @default.
• W2116724316 creator A5041124754 @default.
• W2116724316 creator A5049381472 @default.
• W2116724316 creator A5051180440 @default.
• W2116724316 creator A5062196360 @default.
• W2116724316 creator A5082563606 @default.
• W2116724316 creator A5090399319 @default.
• W2116724316 date "2009-11-01" @default.
• W2116724316 modified "2023-10-06" @default.
• W2116724316 title "Methotrexate for Ocular Inflammatory Diseases" @default.
• W2116724316 cites W1498710999 @default.
• W2116724316 cites W1837356308 @default.
• W2116724316 cites W1967262022 @default.
• W2116724316 cites W1994344663 @default.
• W2116724316 cites W2002804672 @default.
• W2116724316 cites W2002981238 @default.
• W2116724316 cites W2005090786 @default.
• W2116724316 cites W2033363456 @default.
• W2116724316 cites W2036095580 @default.
• W2116724316 cites W2038919542 @default.
• W2116724316 cites W2044532458 @default.
• W2116724316 cites W2046422595 @default.
• W2116724316 cites W2047901258 @default.
• W2116724316 cites W2058287717 @default.
• W2116724316 cites W2058828388 @default.
• W2116724316 cites W2059003657 @default.
• W2116724316 cites W2061198727 @default.
• W2116724316 cites W2061313746 @default.
• W2116724316 cites W2064325706 @default.
• W2116724316 cites W2075592258 @default.
• W2116724316 cites W2084062481 @default.
• W2116724316 cites W2090993184 @default.
• W2116724316 cites W2091566696 @default.
• W2116724316 cites W2095611300 @default.
• W2116724316 cites W2097613586 @default.
• W2116724316 cites W2104569372 @default.
• W2116724316 cites W2105207805 @default.
• W2116724316 cites W2112901522 @default.
• W2116724316 cites W2119333176 @default.
• W2116724316 cites W2127133939 @default.
• W2116724316 cites W2136883754 @default.
• W2116724316 cites W2136967176 @default.
• W2116724316 cites W2139499737 @default.
• W2116724316 cites W2142555697 @default.
• W2116724316 cites W2145307182 @default.
• W2116724316 cites W2156308487 @default.
• W2116724316 cites W2156449368 @default.
• W2116724316 cites W2160077657 @default.
• W2116724316 cites W2165571611 @default.
• W2116724316 cites W2286086659 @default.
• W2116724316 cites W2328999771 @default.
• W2116724316 cites W2331320446 @default.
• W2116724316 cites W2397804311 @default.
• W2116724316 cites W2403866858 @default.
• W2116724316 cites W2415800613 @default.
• W2116724316 cites W27871067 @default.
• W2116724316 cites W2791114118 @default.
• W2116724316 cites W40064359 @default.
• W2116724316 doi "https://doi.org/10.1016/j.ophtha.2009.04.020" @default.
• W2116724316 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3785935" @default.
• W2116724316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19748676" @default.
• W2116724316 hasPublicationYear "2009" @default.
• W2116724316 type Work @default.
• W2116724316 sameAs 2116724316 @default.
• W2116724316 citedByCount "262" @default.
• W2116724316 countsByYear W21167243162012 @default.
• W2116724316 countsByYear W21167243162013 @default.
• W2116724316 countsByYear W21167243162014 @default.
• W2116724316 countsByYear W21167243162015 @default.
• W2116724316 countsByYear W21167243162016 @default.
• W2116724316 countsByYear W21167243162017 @default.
• W2116724316 countsByYear W21167243162018 @default.
• W2116724316 countsByYear W21167243162019 @default.
• W2116724316 countsByYear W21167243162020 @default.
• W2116724316 countsByYear W21167243162021 @default.
• W2116724316 countsByYear W21167243162022 @default.
• W2116724316 countsByYear W21167243162023 @default.
• W2116724316 crossrefType "journal-article" @default.
• W2116724316 hasAuthorship W2116724316A5012888712 @default.
• W2116724316 hasAuthorship W2116724316A5016920591 @default.
• W2116724316 hasAuthorship W2116724316A5022396471 @default.
• W2116724316 hasAuthorship W2116724316A5031802215 @default.
• W2116724316 hasAuthorship W2116724316A5041124754 @default.
• W2116724316 hasAuthorship W2116724316A5049381472 @default.
• W2116724316 hasAuthorship W2116724316A5051180440 @default.
• W2116724316 hasAuthorship W2116724316A5062196360 @default.
• W2116724316 hasAuthorship W2116724316A5082563606 @default.
• W2116724316 hasAuthorship W2116724316A5090399319 @default.
• W2116724316 hasBestOaLocation W21167243162 @default.
• W2116724316 hasConcept C118487528 @default.
• W2116724316 hasConcept C126322002 @default.
• W2116724316 hasConcept C141071460 @default.
• W2116724316 hasConcept C16005928 @default.

• next